DUDE ACCESS SERVICES DAROLUTAMIDE USER DRUG EXPERIENCE
Dead / Abandoned — Abandoned — no statement of use filed (as of 07 Sept 2020)
What this means for you
This application is over — abandoned 07 Sept 2020. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 88537075
- Mark type
- Design + words
- Filed
- 25 Jul 2019
- Published for opposition
- 10 Dec 2019
- Abandoned
- 07 Sept 2020
- Attorney of record
- Christopher J. McHattie
Goods and services
- Class 035 — Advertising and business services: Business administration of patient reimbursement programs; Business administration of pharmaceutical reimbursement programs and services; Business management of reimbursement programs for others; Strategic business planning and consultation in the field of reimbursement support for pharmaceutical products; Business administration of support programs for patients to access co-pay assistance and other funding sources to pay for specialty medications
Owner
- Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ, US
- Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ, US
Prior registrations
Prosecution history
- 08 Sept 2020 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 07 Sept 2020 — ABANDONMENT - NO USE STATEMENT FILED
- 04 Feb 2020 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 10 Dec 2019 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 10 Dec 2019 — PUBLISHED FOR OPPOSITION
- 20 Nov 2019 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 07 Nov 2019 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 06 Nov 2019 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 06 Nov 2019 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 04 Nov 2019 — ASSIGNED TO LIE
- 28 Oct 2019 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 22 Aug 2019 — NOTIFICATION OF PRIORITY ACTION E-MAILED
- 22 Aug 2019 — PRIORITY ACTION E-MAILED
- 22 Aug 2019 — PRIORITY ACTION WRITTEN
- 19 Aug 2019 — ASSIGNED TO EXAMINER